LOY-002: FDA-Approved Drug May Extend Senior Dogs' Lives by 1 Year

Govind Tekale

Biotech firm Loyal has developed LOY-002, a drug that mimics caloric restriction benefits to potentially extend dogs' lifespans.

Generative Medicine Foundation (CC BY-NC 3.0 US)

The FDA's Center for Veterinary Medicine has already accepted the "Reasonable Expectation of Effectiveness" portion of the approval process.

ON POINT LEGAL LEADS (CC BY-NC 4.0)

Large breeds like Great Danes typically live just 6-8 years, while small breeds can reach 12-20 years – a gap this drug aims to narrow.

Photo Source: Flickr (CC BY 2.0)

Loyal's STAY study, involving over 1,000 senior dogs across U.S. clinics, represents the largest veterinary clinical trial in history.

Photo Source: Pexels

Researchers track improvements in energy levels, brain function, and mobility – not just how long dogs live but how well they age.

Photo Source: Stock cake (CC0 1.0)

CEO Celine Halioua emphasizes their goal extends beyond longevity to enhancing quality of life for senior dogs.

Photo Source: The collar club academy (CC BY-NC 4.0)

Dogs share many age-related health problems with humans, making them excellent subjects for aging research.

Photo Source: Flickr (CC BY-NC-SA 2.0)

Success with canine longevity drugs could accelerate similar treatments for humans, as dogs age faster but live in identical environments.

Photo Source: Stock Cake (CC0 1.0)

Loyal has secured $22 million in recent funding, signaling strong investor confidence in the growing pet healthcare technology sector.

Photo Source: Flickr (CC BY-NC-ND 2.0)